Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


ioannis.spiliotis@ocdem.ox.ac.uk

Research groups

Ioannis Spiliotis

BSc (Hons), MBBS, MRCP, DPhil

Clinical Researcher

  • Clinical Researcher, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford
  • Clinical Research Fellow, Oxford University Hospitals NHS Foundation Trust
  • Consultant in Diabetes, Endocrinology and General Medicine, Milton Keynes University Hospital NHS Foundation Trust

Background

I am a consultant physician in diabetes, endocrinology and general medicine, as well as a clinical researcher. My aim is to better understand the effect aberrant glucagon secretion has on the pathophysiology of diabetes, and the impact various pharmacological interventions have on this system.

I have a background in Molecular Biology, and have been working in the field of islet physiology since 2010 alongside my clinical training. I completed my PhD at the University of Oxford in 2018, and I have also worked as part of the clinical islet transplantation team at the Churchill Hospital.

My research work focuses on investigating the hormone secretion profiles of islets in various forms of diabetes, with an emphasis on translating in vitro work into pilot clinical trials. I have completed a CT-IMP (clinical trial of investigational medicinal product) of low-dose sulfonylureas in patients with type 2 diabetes, which demonstrated improvement in fasting hyperglucagonemia. I am now extending this work to clinical studies in patients with MODY (maturity onset diabetes of the young) and type 1 diabetes. 

Clinical trials

2023 (setting-up)               Chief Investigator: Low-doseE GlibENclamdie and Dapagliflozin in Type 1 Diabetes (LEGEND-D) clinical trial

2017 – 2021:                    Chief Investigator: Dapagliflozin during Exercise for the PrevenTion of Hypos (DEPTH) (stopped due to COVID)       (NCT03537131)

2017 – 2022 (completed)    Chief Investigator: Glucagon in MODY (NCT03246828)

2016 – 2017 (completed)    Chief Investigator: Low-doseE GlibENclamdie in Diabetes – part A (LEGEND-A) (NCT02830048)

Websites